Effects and cost-effectiveness of proton pump inhibitor by oral versus injection after endoscopic submucosal dissection

Effects and cost-effectiveness of proton pump inhibitor by oral versus injection after endoscopic submucosal dissection - Effects and cost-effectiveness of proton pump inhibitor by oral versus injection after endoscopic submucosal dissection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011138

Enrollment

100

Registered

2013-07-07

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric tumor(gastric cancer ,gastric adenoma)

Interventions

Patients of oral gruops are received rabeprazole 10mg twice a day by oral for two days from ESD procedure Patients of injection gruops are received lansoprazole 30mg twice a day intravenously

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria are patients with early gastric cancer,gastric adenoma,or suspected gastric neoplasm who are received ESD procedure in Kagawa University.

Exclusion criteria

Exclusion criteria: Patients who can not receive oral administration history of gastric or esophageal surgery drug allergy major organ failure such as cardiac or pulmonary complications

Design outcomes

Primary

Measure	Time frame
The difference of the post-ESD bleeding rate, and the area of ulcer-healing area between two groups after the ESD for 28 days and 56 days	—

Secondary

Measure	Time frame
The difference of cost performance of the proton pump inhibitor, average number of hospitalization days, between by injection and oral.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026